Analysts’ Weekly Ratings Updates for Insulet Corporation (PODD)

A number of research firms have changed their ratings and price targets for Insulet Corporation (NASDAQ: PODD):

• 7/22/2017 – Insulet Corporation had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
• 7/20/2017 – Insulet Corporation was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. “
• 7/18/2017 – Insulet Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $57.00 price target on the stock. According to Zacks, “INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company’s OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. “
• 7/17/2017 – Insulet Corporation was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
• 7/14/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $48.00 price target on the stock.
• 7/14/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $52.00 price target on the stock.
• 7/11/2017 – Insulet Corporation had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $50.00 price target on the stock, up previously from $42.00.
• 6/27/2017 – Insulet Corporation was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
• 6/16/2017 – Insulet Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
• 6/2/2017 – Insulet Corporation was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
• 5/26/2017 – Insulet Corporation had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $42.00 price target on the stock.

Insulet Corporation (NASDAQ PODD) opened at 52.76 on Tuesday. The company’s market cap is $3.06 billion. Insulet Corporation has a 52 week low of $30.69 and a 52 week high of $52.79. The firm’s 50 day moving average is $48.42 and its 200-day moving average is $44.12.

Insulet Corporation (NASDAQ:PODD) last posted its quarterly earnings results on Monday, May 8th. The medical instruments supplier reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. Insulet Corporation had a negative net margin of 6.81% and a negative return on equity of 48.46%. The business had revenue of $101.70 million during the quarter, compared to the consensus estimate of $97.73 million. During the same quarter in the prior year, the firm posted ($0.19) EPS. The company’s revenue for the quarter was up 25.2% compared to the same quarter last year. On average, analysts predict that Insulet Corporation will post ($0.48) earnings per share for the current fiscal year.

In other news, SVP Michael P. Spears acquired 2,500 shares of Insulet Corporation stock in a transaction that occurred on Tuesday, May 16th. The stock was purchased at an average price of $40.59 per share, for a total transaction of $101,475.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David A. Lemoine sold 1,524 shares of the business’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $43.40, for a total transaction of $66,141.60. The disclosure for this sale can be found here. In the last quarter, insiders have purchased 8,080 shares of company stock valued at $317,339. 2.60% of the stock is currently owned by company insiders.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).